Clinical utility of serum type III collagen in patients with pancreatic carcinoma

I Chen, N Willumsen, C Dehlendorff, A Johansen, B V Vittrup, M Krüger, P Pfeiffer, J K Bjerregaard, S E Bojesen, S E Nielsen, N H Holländer, M K Yilmaz, L S Rasmussen, M Karsdal, J S Johansen

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Resumé

Background: Collagen is highly expressed in pancreatic cancer (PC) stroma. Collagen accumulation compromises penetration of macromolecules into tumor tissues and is associated with poorer outcome and increased tumor invasion. The aim of this biomarker study was to investigate the clinical utility of serum pro-peptide of type III collagen (PRO-C3) in patients (pts) with PC.Methods: A cohort from the Danish BIOPAC study (ClinicalTrials.gov ID: NCT03311776) including 851 consecutive subjects with histologically confirmed PC, ampullary carcinoma (n = 45), distal biliary tract cancer (n = 32) and benign lesions (n = 88) were enrolled. Serum PRO-C3 was determined by ELISA (Nordic Bioscience, PRO-C3 protocol). The main outcome was survival among pts with PC (male/female: 458/393; age \lt;50 vs. 50-69 vs. ≥70: 41/477/333; ECOG Performance Status (PS) of 0/1/2+: 315/340/110; stage 1 + 2/3/4: 234/142/456; diabetes yes/no: 207/629; smoking yes/no: 508/265; alcohol yes/no: 183/588; body mass index: low/normal/overweight: 62/426/254; Charlson Age-Comorbidity index (CACI) 0/1-2/3+: 34/296/504) in relation to PRO-C3 levels. Serum CA19-9, hyaluronic acid (HA), C-reactive protein (CRP), interleukin-6 (IL-6) and YKL-40 were measured. Hazard ratios (HRs) and 95\% confidence intervals (CIs) were estimated by Cox proportional hazards regression.
OriginalsprogEngelsk
Artikelnummer752P
TidsskriftAnnals of Oncology
Vol/bind29
Udgave nummerSuppl. 8
Sider (fra-til)viii257
Antal sider1
ISSN0923-7534
DOI
StatusUdgivet - okt. 2018
BegivenhedESMO 2018 Congress (European Society for Medical Oncology): Securing access to optimal cancer care - München, Tyskland
Varighed: 19 okt. 201823 okt. 2018
http://www.esmo.org/Conferences/ESMO-2018-Congress

Konference

KonferenceESMO 2018 Congress (European Society for Medical Oncology)
LandTyskland
ByMünchen
Periode19/10/201823/10/2018
Internetadresse

Citer dette

Chen, I., Willumsen, N., Dehlendorff, C., Johansen, A., Vittrup, B. V., Krüger, M., ... Johansen, J. S. (2018). Clinical utility of serum type III collagen in patients with pancreatic carcinoma. Annals of Oncology, 29(Suppl. 8), viii257. [752P]. https://doi.org/10.1093/annonc/mdy282.135
Chen, I ; Willumsen, N ; Dehlendorff, C ; Johansen, A ; Vittrup, B V ; Krüger, M ; Pfeiffer, P ; Bjerregaard, J K ; Bojesen, S E ; Nielsen, S E ; Holländer, N H ; Yilmaz, M K ; Rasmussen, L S ; Karsdal, M ; Johansen, J S. / Clinical utility of serum type III collagen in patients with pancreatic carcinoma. I: Annals of Oncology. 2018 ; Bind 29, Nr. Suppl. 8. s. viii257.
@article{190b9afab6b2464f97480a407f6fa004,
title = "Clinical utility of serum type III collagen in patients with pancreatic carcinoma",
abstract = "Background: Collagen is highly expressed in pancreatic cancer (PC) stroma. Collagen accumulation compromises penetration of macromolecules into tumor tissues and is associated with poorer outcome and increased tumor invasion. The aim of this biomarker study was to investigate the clinical utility of serum pro-peptide of type III collagen (PRO-C3) in patients (pts) with PC.Methods: A cohort from the Danish BIOPAC study (ClinicalTrials.gov ID: NCT03311776) including 851 consecutive subjects with histologically confirmed PC, ampullary carcinoma (n = 45), distal biliary tract cancer (n = 32) and benign lesions (n = 88) were enrolled. Serum PRO-C3 was determined by ELISA (Nordic Bioscience, PRO-C3 protocol). The main outcome was survival among pts with PC (male/female: 458/393; age \lt;50 vs. 50-69 vs. ≥70: 41/477/333; ECOG Performance Status (PS) of 0/1/2+: 315/340/110; stage 1 + 2/3/4: 234/142/456; diabetes yes/no: 207/629; smoking yes/no: 508/265; alcohol yes/no: 183/588; body mass index: low/normal/overweight: 62/426/254; Charlson Age-Comorbidity index (CACI) 0/1-2/3+: 34/296/504) in relation to PRO-C3 levels. Serum CA19-9, hyaluronic acid (HA), C-reactive protein (CRP), interleukin-6 (IL-6) and YKL-40 were measured. Hazard ratios (HRs) and 95\{\%} confidence intervals (CIs) were estimated by Cox proportional hazards regression.",
author = "I Chen and N Willumsen and C Dehlendorff and A Johansen and Vittrup, {B V} and M Kr{\"u}ger and P Pfeiffer and Bjerregaard, {J K} and Bojesen, {S E} and Nielsen, {S E} and Holl{\"a}nder, {N H} and Yilmaz, {M K} and Rasmussen, {L S} and M Karsdal and Johansen, {J S}",
year = "2018",
month = "10",
doi = "10.1093/annonc/mdy282.135",
language = "English",
volume = "29",
pages = "viii257",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "Suppl. 8",

}

Chen, I, Willumsen, N, Dehlendorff, C, Johansen, A, Vittrup, BV, Krüger, M, Pfeiffer, P, Bjerregaard, JK, Bojesen, SE, Nielsen, SE, Holländer, NH, Yilmaz, MK, Rasmussen, LS, Karsdal, M & Johansen, JS 2018, 'Clinical utility of serum type III collagen in patients with pancreatic carcinoma' Annals of Oncology, bind 29, nr. Suppl. 8, 752P, s. viii257. https://doi.org/10.1093/annonc/mdy282.135

Clinical utility of serum type III collagen in patients with pancreatic carcinoma. / Chen, I; Willumsen, N; Dehlendorff, C; Johansen, A; Vittrup, B V; Krüger, M; Pfeiffer, P; Bjerregaard, J K; Bojesen, S E; Nielsen, S E; Holländer, N H; Yilmaz, M K; Rasmussen, L S; Karsdal, M; Johansen, J S.

I: Annals of Oncology, Bind 29, Nr. Suppl. 8, 752P, 10.2018, s. viii257.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

TY - ABST

T1 - Clinical utility of serum type III collagen in patients with pancreatic carcinoma

AU - Chen, I

AU - Willumsen, N

AU - Dehlendorff, C

AU - Johansen, A

AU - Vittrup, B V

AU - Krüger, M

AU - Pfeiffer, P

AU - Bjerregaard, J K

AU - Bojesen, S E

AU - Nielsen, S E

AU - Holländer, N H

AU - Yilmaz, M K

AU - Rasmussen, L S

AU - Karsdal, M

AU - Johansen, J S

PY - 2018/10

Y1 - 2018/10

N2 - Background: Collagen is highly expressed in pancreatic cancer (PC) stroma. Collagen accumulation compromises penetration of macromolecules into tumor tissues and is associated with poorer outcome and increased tumor invasion. The aim of this biomarker study was to investigate the clinical utility of serum pro-peptide of type III collagen (PRO-C3) in patients (pts) with PC.Methods: A cohort from the Danish BIOPAC study (ClinicalTrials.gov ID: NCT03311776) including 851 consecutive subjects with histologically confirmed PC, ampullary carcinoma (n = 45), distal biliary tract cancer (n = 32) and benign lesions (n = 88) were enrolled. Serum PRO-C3 was determined by ELISA (Nordic Bioscience, PRO-C3 protocol). The main outcome was survival among pts with PC (male/female: 458/393; age \lt;50 vs. 50-69 vs. ≥70: 41/477/333; ECOG Performance Status (PS) of 0/1/2+: 315/340/110; stage 1 + 2/3/4: 234/142/456; diabetes yes/no: 207/629; smoking yes/no: 508/265; alcohol yes/no: 183/588; body mass index: low/normal/overweight: 62/426/254; Charlson Age-Comorbidity index (CACI) 0/1-2/3+: 34/296/504) in relation to PRO-C3 levels. Serum CA19-9, hyaluronic acid (HA), C-reactive protein (CRP), interleukin-6 (IL-6) and YKL-40 were measured. Hazard ratios (HRs) and 95\% confidence intervals (CIs) were estimated by Cox proportional hazards regression.

AB - Background: Collagen is highly expressed in pancreatic cancer (PC) stroma. Collagen accumulation compromises penetration of macromolecules into tumor tissues and is associated with poorer outcome and increased tumor invasion. The aim of this biomarker study was to investigate the clinical utility of serum pro-peptide of type III collagen (PRO-C3) in patients (pts) with PC.Methods: A cohort from the Danish BIOPAC study (ClinicalTrials.gov ID: NCT03311776) including 851 consecutive subjects with histologically confirmed PC, ampullary carcinoma (n = 45), distal biliary tract cancer (n = 32) and benign lesions (n = 88) were enrolled. Serum PRO-C3 was determined by ELISA (Nordic Bioscience, PRO-C3 protocol). The main outcome was survival among pts with PC (male/female: 458/393; age \lt;50 vs. 50-69 vs. ≥70: 41/477/333; ECOG Performance Status (PS) of 0/1/2+: 315/340/110; stage 1 + 2/3/4: 234/142/456; diabetes yes/no: 207/629; smoking yes/no: 508/265; alcohol yes/no: 183/588; body mass index: low/normal/overweight: 62/426/254; Charlson Age-Comorbidity index (CACI) 0/1-2/3+: 34/296/504) in relation to PRO-C3 levels. Serum CA19-9, hyaluronic acid (HA), C-reactive protein (CRP), interleukin-6 (IL-6) and YKL-40 were measured. Hazard ratios (HRs) and 95\% confidence intervals (CIs) were estimated by Cox proportional hazards regression.

U2 - 10.1093/annonc/mdy282.135

DO - 10.1093/annonc/mdy282.135

M3 - Conference abstract in journal

VL - 29

SP - viii257

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - Suppl. 8

M1 - 752P

ER -

Chen I, Willumsen N, Dehlendorff C, Johansen A, Vittrup BV, Krüger M et al. Clinical utility of serum type III collagen in patients with pancreatic carcinoma. Annals of Oncology. 2018 okt;29(Suppl. 8):viii257. 752P. https://doi.org/10.1093/annonc/mdy282.135